Immunotherapy (NHS-IL12 & Bintrafusp Alfa) and Radiation Therapy for the Treatment of Hormone Receptor Positive, HER2 Negative Metastatic Breast Cancer, the REINA Trial
Status: WITHDRAWN
Study type: INTERVENTIONAL
Conditions: Anatomic Stage IV Breast Cancer AJCC v8|Hormone Receptor Positive Breast Adenocarcinoma|Metastatic Breast Carcinoma|Metastatic HER2 Negative Breast Adenocarcinoma|Prognostic Stage IV Breast Cancer AJCC v8
Interventions: DRUG: Bintrafusp Alfa|BIOLOGICAL: Immunocytokine NHS-IL12|RADIATION: Radiation Therapy
Sponsor: M.D. Anderson Cancer Center